A Pantetheinase-Resistant Pantothenamide with Potent, On-Target, and Selective Antiplasmodial Activity

Cristiano J. Macuamule, a Erick T. Tjhin, b Collins E. Jana, a Leanne Barnard, a Lizbé Koekemoer, a Marianne de Villiers, a Kevin J. Saliba, b,c Erick Strauss a

Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa a; Research School of Biology, College of Medicine, Biology, and Environment, The Australian National University, Canberra, ACT, Australia b, c; Medical School, College of Medicine, Biology, and Environment, The Australian National University, Canberra, ACT, Australia a

Pantothenamides inhibit blood-stage Plasmodium falciparum with potencies (50% inhibitory concentration [IC50], ~20 nM) similar to that of chloroquine. They target processes dependent on pantothenate, a precursor of the essential metabolic cofactor coenzyme A. However, their antiplasmodial activity is reduced due to degradation by serum pantetheinase. Minor modification of the pantothenamide structure led to the identification of α-methyl-N-phenethyl-pantothenamide, a pantothenamide resistant to degradation, with excellent antiplasmodial activity (IC50, 52 ± 6 nM), target specificity, and low toxicity.


Address correspondence to Erick Strauss, estrauss@sun.ac.za.

C.J.M. and E.T.T. contributed equally to this article.

Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.04970-14.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.04970-14

One-half of the world's population (~3.4 billion people) is at risk of contracting malaria, with pregnant women and children <5 years of age being especially vulnerable. In 2013, the WHO estimated that malaria caused ~584,000 deaths globally, with the majority occurring in Africa (1). Although efforts to control and to eliminate malaria in the past 15 years have saved an estimated 3.3 million lives (1), drug-resistant parasites continue to emerge (2). This places the progress in the fight against the disease under pressure, especially since there is no effective vaccine against malaria (3). Several new drug targets have been identified in recent years (4); however, these targets now need to be exploited through the development of directed treatments.

We are interested in targeting the biosynthesis of the essential cofactor coenzyme A (CoA) from the water-soluble vitamin B5 (pantothenate, compound 1 in Fig. 1) for antimalarial drug development (5, 6). It has been shown that extracellular pantothenate is essential for intracellular malaria parasites (7), which indicates that Plasmodium falciparum does not utilize exogenous CoA but must synthesize CoA de novo (8).

Pantothenate analogues interfere with the ability of P. falciparum to utilize the vitamin, with many analogues being characterized as growth inhibitors of the blood-stage parasites (9–11). Furthermore, a recent study showed that CoA biosynthesis can be targeted by a chemically diverse set of inhibitors that do not resemble pantothenate, the most potent of which had a 50% inhibitory concentration (IC50, the concentration that inhibits parasite proliferation by 50%) of 120 nM against blood-stage parasites (12). These studies support pantothenate utilization (and therefore CoA biosynthesis and CoA-dependent processes) as an antiplasmodial target.

Recently we showed that N-substituted pantothenamides (PanAms), a specific class of pantothenate analogues, have excellent antiplasmodial activity. Among these, N-phenethyl-pantothenamide (N-PE-PanAm) (compound 2 in Fig. 1) exhibited an IC50 of 20 nM (13); this potency is comparable to that of chloroquine (14, 15). In practice, however, the antiplasmodial activity of the PanAms is decreased since they are degraded by pantetheinase (13), a ubiquitous enzyme of the Vanin protein family that is present in serum (16, 17). Pantetheinase normally catalyzes the hydrolysis of pantetheine (a CoA-derived metabolite) to form pantothenate and cysteamine (18, 19), but it also acts on compounds with a wide range of variations in the cysteamine moiety, including the PanAms (Fig. 1) (13). In a previous study, we found that replacement of the alanine moiety of the PanAms with either glycine or γ-aminobutyric acid gave rise to pantetheinase-resistant variants, due to displacement of the scissile amide bond (20). Unfortunately, these structural modifications also reduced the potency of the resulting PanAms (IC50 values of ≥1 μM), indicating that their target (or targets) requires the pantothenate core structure to be retained for optimal inhibition.

In light of this finding, we set out to develop a pantetheinase-resistant PanAm in which the alanine core was retained. This was achieved by adding a methyl group to the carbon adjacent to the amide carbonyl group, thereby increasing the steric bulk at this center. We predicted that this modification would reduce the rate of pantetheinase-mediated hydrolysis by limiting the access of the enzyme’s cysteine nucleophile to the scissile amide bond. The methylated version of N-PE-PanAm, i.e., α-methyl-N-PE-PanAm (α-Me-N-PE-PanAm) (compound 3 in Fig. 1), was prepared by condensing D,L-3-amino-isobutyrate to pantolactone, followed by partial purification by cation-exchange chromatography. The product, α-methyl-D-pantothenate, was purified by flash column chromatography (FCC) before being coupled to N-phenethylamine using diphenylphosphoryl azide in the presence of triethylamine. After purification by FCC, α-Me-N-PE-PanAm was...
Stable, On-Target, Antiplasmodial Pantothenamide

**FIG 1** (Left) Structure of N-PE-PanAm (compound 2), which can be degraded by pantetheinase (Vanin) to form pantothenate (compound 1) and phenethylamine. (Right) Structure of α-Me-N-PE-PanAm (compound 3), which shows limited degradation by pantetheinase. The vulnerable (scissile) amide bond is indicated by the oval on the left, while the shaded oval on the right shows how it is modified by introduction of the methyl group to increase stability.

obtained in a final overall yield of 45%, as a mixture of two epimers (see the supplemental material for more details).

The antiplasmodial activity of α-Me-N-PE-PanAm against the chloroquine-sensitive *P. falciparum* strain 3D7 (chloroquine IC$_{50}$, 11 ± 1 nM [mean ± standard error of the mean (SEM)]; n = 3) was determined in “aged medium” (i.e., medium in which pantetheinase had been inactivated by incubation at 37°C for 40 h), in a manner similar to that used previously for N-PE-PanAm (13, 20). Under these conditions, α-Me-N-PE-PanAm showed excellent antiplasmodial activity, with an IC$_{50}$ of 29 ± 2 nM (mean ± SEM; n = 3), a value that is only slightly greater than that of N-PE-PanAm (Fig. 2a). Furthermore, α-Me-N-PE-PanAm demonstrated exceptional resistance to degradation by pantetheinase, compared to N-PE-PanAm, as can be seen from its antiplasmodial activity in normal medium (i.e., with active pantetheinase), with an IC$_{50}$ of 52 ± 6 nM (mean ± SEM; n = 3) (Fig. 2a), compared to the N-PE-PanAm IC$_{50}$ of ~6,200 nM (13, 20). Performing the same test with a chloroquine-resistant strain (strain Dd2; chloroquine IC$_{50}$, 173 ± 5 nM [mean ± range/2]; n = 2) gave an IC$_{50}$ of 129 ± 4 nM (mean ± range/2; n = 2); based on currently available data, it is unclear whether this difference is related to chloroquine resistance or is merely a variation in strain sensitivity. More importantly, resistance to pantetheinase degradation did not come at a cost in target specificity, since addition of excess extracellular pantothenate (100 μM) to the medium antagonized the antiplasmodial activity of α-Me-N-PE-PanAm against the 3D7 strain (IC$_{50}$, 860 ± 102 nM [mean ± SEM]; n = 3; P = 0.01) (Fig. 2a).

To confirm the stability of α-Me-N-PE-PanAm, we also tested its *in vitro* degradation by recombinant pantetheinase (human VNN1) (Fig. 2b). This was done by incubating substrate (500 μM N-PE-PanAm or α-Me-N-PE-PanAm; 500 μM phenethylamine was used as a reference, i.e., equivalent to 100% product formation) in 100 mM HEPES (pH 7.6) containing 500 μM dithiothreitol (DTT) and 0.05 μg/μl bovine serum albumin (BSA), at 37°C. The reaction (in a final volume of 300 μl) was initiated by the addition of pantetheinase (1.6 μg/μl), and the mixture was incubated for 24 h. The amount of amine produced was determined by quenching 30 μl of the reaction mixture with 10 μl of N-ethylmaleimide (6 μM), followed by incubation (for 10 min at 37°C) with 2 mM fluorescamine in 517 mM borate (pH 9), in a final volume of 145 μl. Fluorescence was subsequently measured using a Thermo Varioskan multiplate spectrofluorimeter (excitation wavelength, 395 nm; emission wavelength, 485 nm). We were able to confirm that α-Me-N-PE-PanAm was more resistant to pantetheinase-mediated degradation than N-PE-PanAm, as it showed only 26% ± 2% (mean ± range/2; n = 2) hydrolysis (normalized to the control, which represented 100% phenethylamine formed) after 24 h, compared to 96% ± 9% (mean ± range/2; n = 2) for N-PE-PanAm under the same conditions.

The activity of α-Me-N-PE-PanAm was tested against a human cell line (human foreskin fibroblasts [HFF]) to determine its selectivity (21). The cells were exposed to α-Me-N-PE-PanAm
(0.781 to 100 μM) for 4 days to reach confluence, and plates were stored at ~80°C prior to exposure to SYBR Safe, as was done for the parasite experiments. We found that α-Me-N-Pe-PanAm had limited cytotoxicity for HFF cells, with a selectivity index (SI) greater than 1,500 (Fig. 2c), rivalling the SI of chloroquine.

With these promising findings, we unveil α-Me-N-Pe-PanAm as the first pantothenate analogue with excellent potential as a new lead compound for antimalarial drug development, based on its potent inhibition of blood-stage parasites in the presence of serum pantetheinase, lack of activity against human cells, and desirable physicochemical characteristics (22) (see the supplemental material for details). Future work will focus on determining whether the two epimers show a difference in activity, performing tests on other stages of the parasite’s life cycle, and determining the pharmacokinetic properties and in vivo efficacy of α-Me-N-Pe-PanAm, to establish its long-term potential for development as an antimalarial.

ACKNOWLEDGMENTS

Aspects of this work were supported by a grant from the South African Malaria Initiative to K.J.S. and E.S. Australia Awards Small Grants Scheme, an initiative of the Australian Government (to C.J.M.), made visits to the Australian National University possible and are gratefully acknowledged. C.J.M. was supported by a Canon Collins Trust Scholarship. E.T.T. was supported by an International Postgraduate Research Scholarship from the Australian government. C.E.J., L.B., and L.K. were supported by bursaries and fellowships from the National Research Foundation of South Africa. M.D.V. was supported by the National Research Foundation of South Africa as a Research Career Advancement Fellow.

We are grateful to the Canberra Branch of the Australian Red Cross Blood Service for the provision of red blood cells and the van Dooren laboratory at the Australian National University for providing the HFF cells.

REFERENCES